346 related articles for article (PubMed ID: 21810157)
1. Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment.
Marcelissen TA; Leong RK; Nieman FH; van Lankveld JJ; van Kerrebroeck PE; de Wachter SG
BJU Int; 2011 Dec; 108(11):1834-8. PubMed ID: 21810157
[TBL] [Abstract][Full Text] [Related]
2. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy.
Leong RK; De Wachter SG; Nieman FH; de Bie RA; van Kerrebroeck PE
Neurourol Urodyn; 2011 Sep; 30(7):1249-52. PubMed ID: 21404317
[TBL] [Abstract][Full Text] [Related]
3. Prolonged percutaneous SNM testing does not cause infection-related explanation.
Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
[TBL] [Abstract][Full Text] [Related]
4. The effect of pulse rate changes on the clinical outcome of sacral neuromodulation.
Marcelissen TA; Leong RK; Nieman FH; de Bie RA; van Kerrebroeck PE; de Wachter SG
J Urol; 2011 May; 185(5):1781-5. PubMed ID: 21420118
[TBL] [Abstract][Full Text] [Related]
5. The value of urodynamic tools to guide patient selection in sacral neuromodulation.
Drossaerts J; Rademakers K; van Koeveringe G; Van Kerrebroeck P
World J Urol; 2015 Nov; 33(11):1889-95. PubMed ID: 25680936
[TBL] [Abstract][Full Text] [Related]
6. Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation.
Drossaerts J; Vrijens D; Leue C; Schilders I; Van Kerrebroeck P; van Koeveringe G
Neurourol Urodyn; 2016 Nov; 35(8):1011-1016. PubMed ID: 26351817
[TBL] [Abstract][Full Text] [Related]
7. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
Parnell BA; Howard JF; Geller EJ
Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of sacral neuromodulation with the tined lead procedure.
Marcelissen TA; Leong RK; de Bie RA; van Kerrebroeck PE; de Wachter SG
J Urol; 2010 Nov; 184(5):1997-2000. PubMed ID: 20850820
[TBL] [Abstract][Full Text] [Related]
9. Is sensory testing during lead placement crucial for achieving positive outcomes after sacral neuromodulation?
Peters KM; Killinger KA; Boura JA
Neurourol Urodyn; 2011 Nov; 30(8):1489-92. PubMed ID: 21674596
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Duration of Complaints on Successful Outcome of Sacral Neuromodulation.
Jairam R; Drossaerts J; van Koeveringe G; van Kerrebroeck P
Urol Int; 2017; 99(1):51-55. PubMed ID: 28478446
[TBL] [Abstract][Full Text] [Related]
11. Sacral neuromodulation in urological indications: the Finnish experience.
Vaarala MH; Tammela TL; Perttilä I; Luukkonen P; Hellström P
Scand J Urol Nephrol; 2011 Feb; 45(1):46-51. PubMed ID: 20961268
[TBL] [Abstract][Full Text] [Related]
12. Affective symptoms and quality of life in patients with voiding or storage dysfunction: Results before and after sacral neuromodulation: A prospective follow-up study.
Jairam R; Drossaerts J; Vrijens D; Leue C; van Kerrebroeck P; van Koeveringe G
Neurourol Urodyn; 2018 Jun; 37(5):1801-1808. PubMed ID: 29504634
[TBL] [Abstract][Full Text] [Related]
13. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
[TBL] [Abstract][Full Text] [Related]
14. Sacral neuromodulation for treating the symptoms of overactive bladder syndrome and non-obstructive urinary retention: >10 years of clinical experience.
Chartier-Kastler E
BJU Int; 2008 Feb; 101(4):417-23. PubMed ID: 18070181
[No Abstract] [Full Text] [Related]
15. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
Girtner F; Burger M; Mayr R
Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for successful percutaneous tibial nerve stimulation.
van Balken MR; Vergunst H; Bemelmans BL
Eur Urol; 2006 Feb; 49(2):360-5. PubMed ID: 16359781
[TBL] [Abstract][Full Text] [Related]
17. [Sacral neuromodulation in patients with nonobstructive, chronic urinary retention: relevance of the carbachol test and influence of associated nerve lession].
Bross S; Braun PM; Weiss J; Martinez Portillo FJ; Knoll T; Seif C; Jünemann KP; Alken P
Aktuelle Urol; 2003 May; 34(3):157-61. PubMed ID: 14566686
[TBL] [Abstract][Full Text] [Related]
18. [Results of sacral posterior neuromodulation on voiding disorders and impact on sexuality based on a single-center study].
Ferhi K; Miaadi N; Tanneau Y; Leroi AM; Sibert L; Grise P
Prog Urol; 2008 Mar; 18(3):160-6. PubMed ID: 18472068
[TBL] [Abstract][Full Text] [Related]
19. Onset of Action of Sacral Neuromodulation in Lower Urinary Tract Dysfunction-What is the Optimal Duration of Test Stimulation?
Jairam R; Drossaerts J; Marcelissen T; van Koeveringe G; van Kerrebroeck P
J Urol; 2018 Jun; 199(6):1584-1590. PubMed ID: 29291416
[TBL] [Abstract][Full Text] [Related]
20. Is the screening method of sacral neuromodulation a prognostic factor for long-term success?
Marcelissen T; Leong R; Serroyen J; van Kerrebroeck P; de Wachter S
J Urol; 2011 Feb; 185(2):583-7. PubMed ID: 21168865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
